284 afleveringen
NCBiotech on North Carolina Biomanufacturing Talent, Investment, and Geopolitics
19-11-2026 | 29 Min.“It’s an easy move to say, ‘Oh, you’re becoming victims of your own success. Where do I find my talent?’ And I would argue you’re going to find it exactly where you found it before, and there’s plenty of it,” says Bill Bullock.
Bill Bullock is Senior Vice President of Economic and Statewide Development at the North Carolina Biotechnology Center (NCBiotech). He trained as a biochemist and worked at the bench for a California startup before doing an MBA at UNC Chapel Hill. He joined NCBiotech in 2003 to build out its economic development function, and has spent more than two decades bringing life sciences companies to the state.
North Carolina now employs roughly 36,000 people in life sciences manufacturing. Since January 2022, the state has recorded 67 life sciences company expansions and more than 10,000 announced jobs. In the past year alone, AbbVie, Genentech, J&J Innovative Medicine, and Novartis have all announced expansions, and FUJIFILM Biotechnologies opened its Holly Springs biomanufacturing facility. In the latest PharmaSource podcast episode, Bill explains what is drawing manufacturers to North Carolina, how the state keeps its talent pipeline ahead of demand, and where it still needs to catch up.
Read the full article.- At CDMO Live Americas, a panel of procurement leaders shared how better RFPs, shared incentives, and two-way governance turn CDMO contracts into lasting alliances.
“We measure On-Time In-Full down to the decimal point, but we don’t even know if we trust each other.” Daniel Marasco said he once heard that line from a colleague, and it sums up a problem in many outsourcing relationships: the performance metrics are precise, but the trust behind them is weak.
Marasco was joined by Frederik Krekeler, Head of Procurement Consumer Health North America at Bayer; Susan Camden, Vice President of Business Development at Kindeva; and Lindsay Pope, Founder of Apothecary Consulting
Read the article - “We talk about external manufacturing and managing CDMOs, but 90% of your time is managing the internal team,” says Tamika Drummond.
Dr. Tamika Drummond, CEO and Founder of 3Kinnect Solutions, holds a master’s in pharmacology and a PhD in chemistry. She built her career at a prominent Canadian biotech, where she led CDMO selection, onboarding, and partnership management across biologics, monoclonal antibodies, bispecifics, and ADC programs. Before that, she worked in teaching, project management, and GMP quality assurance.
In the latest PharmaSource podcast episode, Tamika explains why CDMO selection is one of the most consequential decisions an early-stage biotech will make. She also explains why the choices that shape a program’s manufacturing future are usually made much earlier than most teams realize.
Read the full article. DC Decoded: How Section 232 Tariffs and FDA Upheaval Are Reshaping US Contract Manufacturing
09-11-2026 | 52 Min.Gil Roth, President of PBOA, and Marta Wosińska, Senior Fellow at the Brookings Institution, told CDMO Live Americas that the headline tariff rate matters far less to contract manufacturers than who actually pays it.
A 100% tariff sounds like a powerful reason to move drug manufacturing to the US. For most of the contract manufacturing market, it is not. That was a takeaway from Marta Wosińska, Senior Fellow at the Brookings Institution, in a fireside chat with Gil Roth, President of the Pharma & Biopharma Outsourcing Association (PBOA), at CDMO Live Americas 2026 in October.
Roth opened the session by discussing a Washington agenda he called 'contradictory', chasing lower drug prices and domestic manufacturing at once. Wosińska then took the audience inside the Section 232 tariffs at its center.
Download Partnerships Under Pressure, the full report from CDMO Live Americas 2026Manufacturing Network Strategy: “You Can’t Have Your Cake and Eat It”: Pfizer, Biogen, Astellas and ROIS
02-11-2026 | 35 Min.Policy shifts, tariff threats and a wave of U.S. investment announcements have left outsourcing leaders asking the same question: do you consolidate to fewer, deeper CDMO partnerships, or spread out to protect supply?
That was the debate at CDMO Live Americas in Boston, where a panel session explored manufacturing network optimization. The session, sponsored by ROIS, brought together:
Joseph Graskemper, General Manager, Early Phase Development & Manufacturing, Biogen
Gretchen Peck, Senior Director, Strategy & Program Management, Pfizer
Amber Meriwether, Corporate Strategy, Astellas
Kimberlee Steele, Chief Commercial Officer, ROIS
Read the full article
Meer Levenswetenschappen podcasts
Trending Levenswetenschappen -podcasts
Over PharmaSource Podcast
Welcome to the PharmaSource podcast: the pharma and biotech podcast that explores the latest trends, challenges, and commercial opportunities shaping the biopharma manufacturing and outsourcing.
In each episode we'll be speaking with top executives, researchers, and outsourcing experts, who share their perspectives on topics such as building a smarter, more sustainable supply chain, how to partner with CDMOs, digital transformation, procurement and external manufacturing strategies, and plenty more besides.
Make sure to subscribe for your regular dose of pharma insight.
Podcast websiteLuister naar PharmaSource Podcast, The Quanta Podcast en vele andere podcasts van over de hele wereld met de radio.net-app

Ontvang de gratis radio.net app
- Zenders en podcasts om te bookmarken
- Streamen via Wi-Fi of Bluetooth
- Ondersteunt Carplay & Android Auto
- Veel andere app-functies




















